Figures computed from official regulatory filings — .
Analysttarget 29.77 USD (+72%) · consensus 4.24/5 · 11 buy · 6 hold · 0 sell
Ownershipinsiders 80.89% · institutions 17.58% · short 26.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Summit Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
39 buys5 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Zanganeh Makytrack record | Buy | $50M | conv 60 |
| SEC |
| DUGGAN ROBERT Wtrack record | Buy | $50M | conv 60ClusterUnusual size | SEC |
| DUGGAN ROBERT Wtrack record | Buy | $1.5M | conv 40Cluster | SEC |
| Soni Manmeet Singhtrack record | Buy | $360.8K | conv 53ClusterFirst in 12mo | SEC |
| Soni Manmeet Singhtrack record | Buy | $361.5K | conv 53ClusterFirst in 12mo | SEC |
| Zanganeh Makytrack record | Buy | $1.5M | conv 44Cluster | SEC |
| Anand Bhaskar | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Booth Robert F. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Clark Kenneth A | AwardD (derivative) | $155.9K | Unusual size | SEC |
| Huber Jeff | AwardD (derivative) | $86.6K | SEC |
| Clark Kenneth A | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Huber Jeff | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Xia Yu | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Zanganeh Makytrack record | AwardD (derivative) | $98.4K | SEC |
| Cesano Alessandra | AwardD (derivative) | $28.2K | SEC |
| Cesano Alessandra | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ronaghi Mostafa | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Booth Robert F. | AwardD (derivative) | $62.9K | Unusual size | SEC |
| DUGGAN ROBERT Wtrack record | AwardD (derivative) | $98.4K | SEC |
| DUGGAN ROBERT Wtrack record | Award | $5M | SEC |
| Soni Manmeet Singhtrack record | Award | $1M | Unusual size | SEC |
| Anand Bhaskar | Award | $500K | Unusual size | SEC |
| DUGGAN ROBERT Wtrack record | Award | $262M | Unusual size | SEC |
| Zanganeh Makytrack record | Award | $5M | Unusual size | SEC |
| Zanganeh Makytrack record | Award | $262M | Unusual size | SEC |